Cizzle Bio is excited to welcome Jennifer Hinkel, MSc, as Senior Consultant, Economics & Commercialization. With 15+ years of experience in health economics, market access, and oncology commercialization, she brings invaluable expertise to expand Cizzle Bio’s diagnostic solutions and ensure patient access to early cancer detection.

Cizzle Bio is proud to welcome Yolanda Heiberger, M.A., as Vice President of Communications & Patient Education. With a background in healthcare communications and patient engagement, she will play a key role in advancing education and awareness for early cancer detection.

Cizzle Bio is excited to welcome Dr. Steve Henderson as our Senior Consultant, Grant Writing & Research. With a strong background in biomedical research, clinical trials, and securing funding for scientific advancements, Dr. Henderson brings invaluable expertise to support Cizzle Bio’s innovation in early cancer detection.

Cizzle Bio proudly announces Dr. Steven T. Rosen, an esteemed leader in oncology, as our newest Scientific Advisor. Dr. Rosen brings decades of experience in cancer research and clinical care to support our mission of improving early cancer detection and saving lives.

Cizzle Bio proudly announces Dr. Ajay Goel as our new Scientific Advisor. With over 25 years of groundbreaking cancer research, Dr. Goel’s expertise in biomarkers and diagnostics will play a key role in advancing early cancer detection technologies.

Cizzle Bio, Inc. proudly announces the appointment of Joseph Kelley, retired Eli Lilly Executive, to its Board of Directors. With over 25 years of experience in business, public policy, and regulatory affairs, Mr. Kelley brings exceptional leadership to support Cizzle Bio’s mission to revolutionize early cancer detection.

We are excited to announce that Dr. William S. Dalton, renowned oncology expert and former CEO of Moffitt Cancer Center, has joined Cizzle Bio, Inc. as the Head of Clinical Trials. Dr. Dalton’s extensive experience in precision medicine and cancer research will play a vital role in advancing our innovative diagnostic solutions for early cancer detection.

Cizzle Bio, Inc. has entered into a strategic partnership with BBI Solutions to manufacture commercial monoclonal antibodies for early-stage lung cancer detection. This collaboration marks a significant milestone in Cizzle Bio's mission to bring the CIZ1B biomarker test to market. The first batch will support up to 5000 tests and facilitate critical clinical evaluations with a major US cancer center.